This study will help clinical, safety, procurement, and senior management teams to understand the value of implementing NGPOD as an alternative to obtaining the existing approach, aspirate and pH strip testing for patients who need hydration, nutrition or medication through a nasogastric tube.
The study is taking place on stroke wards in both Hywel Dda and Swansea Bay Health Boards and will evaluate the clinical acceptability, cost-effectiveness and impact on patient outcomes in real-world settings on NGPOD.
Marcus Ineson, Chief Marketing Officer for NGPOD Global Ltd, said of the project,
"We know from the NGPOD clinical trial that the system is safe and more effective than current methods when used in a research situation. However, small, less formal evaluations in real-world environments have shown even better results than the trial. The exciting thing about this service evaluation is that we will now be able to determine the impact of NGPOD on outcomes and value to the healthcare system using the expertise of Tritech within Wales, which is a world leader in Value-Based Healthcare."
The results of the Service Evaluation are due to be available in June 2022.
NGPOD is a patented device that, in a UK based clinical trial, has been shown to reduce the risks associated with established methods of nasogastric tube placement, which can lead to serious clinical incidents (Never Events) which cause injury and death to patients. NGPOD also reduces the need for time-consuming, costly x-rays and allows patients to receive nutrition, hydration and medicines without delay supporting their recovery.
To read the article from Life Sciences Hub Wales
WHAT IS NGPOD?